Posted by Michael Wonder on 04 Oct 2022
Theratechnologies’ Trogarzo approved by FDA for 30 second intravenous push, simplifying HIV treatment for heavily treatment experienced population
3 October 2022 - Reduces maintenance dose from a 15 minute intravenous infusion to a 30 second, undiluted intravenous push every two weeks.
Theratechnologies today announced that the US FDA approved Trogarzo (ibalizumab-uiyk) for administration by intravenous push, a method by which the undiluted medication is “pushed” by syringe for faster administration into the body’s circulation.
Read Theratechnologies press release
